ESR1 and breast cancer: Distinguishingly, among all types of BC, triple negative BC (TNBC) tends to have the worst prognosis due to the lack of therapeutic targeting of ER, progesterone receptor (PR), and epidermal growth factor receptor 2 (HER-2) 46.